Table 3.
Associations of Outcomes and Clinicopathological Features in 109 Gastric Cancer Patients.
| Characteristics | No. of patients (%) | Outcome | p (χ2) | |
|---|---|---|---|---|
| Survival | Death | |||
| Age group | 0.501(a) | |||
| <30 | 1 (0.9) | 0 | 1 (2.6) | |
| 30-39 | 11 (10.1) | 7 (10.0) | 4 (10.3) | |
| 40-49 | 12 (11.0) | 6 (8.6) | 6 (15.4) | |
| 50-59 | 40 (36.7) | 28 (40.0) | 12 (30.8) | |
| ≥60 | 45 (41.3) | 29 (41.4) | 16 (41.0) | |
| Sex | 0.410 | |||
| Male | 68 (62.4) | 46 (65.7) | 22 (56.4) | |
| Female | 41 (37.6) | 24 (34.3) | 17 (43.6) | |
| Location | 0.775(a) | |||
| Antrum | 87 (79.8) | 56 (80.0) | 31 (79.5) | |
| Antrum—Lesser curvature | 7 (6.4) | 5 (7.1) | 2 (5.1) | |
| Fundus/Corpus | 5 (4.6) | 4 (5.7) | 1 (2.6) | |
| Corpus—Lesser curvature | 3 (2.8) | 1 (1.4) | 2 (5.1) | |
| Cardia | 3 (2.8) | 1 (1.4) | 2 (5.1) | |
| Pyloric antrum | 3 (1.8) | 1 (1.4) | 1 (5.1) | |
| Unknown | 1 (0.9) | 1 (1.4) | 0 | |
| Histopathological type | 0.003(a) | |||
| Adenocarcinoma, NOS | 86 (78.9) | 62 (88.6) | 24 (61.5) | |
| Signet ring cell | 16 (14.7) | 5 (7.1) | 11 (28.2) | |
| Mucinous | 7 (6.4) | 3 (4.3) | 4 (10.3) | |
| Histological grade | 0.533 | |||
| Well-differentiated | 7 (8.1) | 6 (9.7) | 1 (4.2) | |
| Moderately-differentiated | 36 (41.9) | 27 (43.5) | 9 (37.5) | |
| Poorly-differentiated | 43 (50.0) | 29 (46.8) | 14 (58.3) | |
| Lauren classification | 0.004 | |||
| Intestinal type | 93 (85.3) | 65 (92.9) | 28 (71.8) | |
| Diffuse type | 16 (14.7) | 5 (7.1) | 11 (28.2) | |
| Tumor Budding | <0.001 | |||
| Low | 59 (54.1) | 55 (78.6) | 4 (10.3) | |
| High | 50 (45.9) | 15 (21.4) | 35 (89.7) | |
| LVI | <0.001 | |||
| Absent | 67 (61.5) | 54 (77.1) | 13 (33.3) | |
| Present | 42 (38.5) | 16 (22.9) | 26 (66.7) | |
| Perineural invasion | <0.001 | |||
| Absent | 68 (62.4) | 55 (78.6) | 13 (33.3) | |
| Present | 41 (37.6) | 15 (21.4) | 26 (66.7) | |
| Lymph node status | 0.027(a) | |||
| Negative | 40 (36.7) | 32 (45.7) | 8 (20.5) | |
| 1-2 positive node(s) | 42 (38.5) | 26 (37.1) | 16 (41.0) | |
| 3-6 positive nodes | 17 (15.6) | 8 (11.4) | 9 (23.1) | |
| 7-15 positive nodes | 9 (8.3) | 4 (5.7) | 5 (12.8) | |
| > 15 positive nodes | 1 (0.9) | 0 | 1 (2.6) | |
| pTNM stage | 0.045(a) | |||
| I | 3 (2.8) | 3 (4.3) | 0 | |
| IIA | 24 (22.0) | 20 (28.6) | 4 (10.3) | |
| IIB | 24 (22.0) | 17 (24.3) | 7 (17.9) | |
| IIIA | 21 (19.3) | 12 (17.1) | 9 (23.1) | |
| IIIB | 26 (23.9) | 14 (20.0) | 12 (30.8) | |
| IIIC | 11 (10.1) | 4 (5.7) | 7 (17.9) | |
| Relapse | <0.001 | |||
| Absent | 78 (71.6) | 69 (88.5) | 9 (11.5) | |
| Present | 31 (28.4) | 1 (3.2) | 30 (96.8) | |
| Metastatic pattern | 0.75(a) | |||
| Locoregional metastasis | 7 (25.0) | 0 | 7 (100.0) | |
| Distant metastasis | 21 (75.0) | 1 (4.8) | 20 (95.2) | |
(a): Fisher exact test.